Bionano Genomics (NASDAQ: BNGO) interim CEO buys 4,000 shares

Rhea-AI Filing Summary

Bionano Genomics, Inc. (BNGO) reported that interim Chief Executive and director Albert Luderer indirectly purchased 4,000 shares of Common Stock on 2026-08-21 in an open-market or private transaction at $1.215 per share. The shares are held indirectly through a Traditional IRA, and this filing does not indicate use of a Rule 10b5-1 trading plan.

Insider Trade Summary

Net Buyer: 4,000 shares

Net Buy 1 txn

Insider Luderer Albert

Role Interim Chief Executive

Bought 4,000 shs ($5K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	4,000	$1.215	$5K

Holdings After Transaction: Common Stock — 4,000 shares (Indirect, Traditional IRA)

Key Figures

Shares purchased: 4,000 shares Purchase price per share: $1.215 per share Shares owned after transaction: 4,000 shares

3 metrics

Shares purchased 4,000 shares Common Stock purchased on 2026-08-21

Purchase price per share $1.215 per share Open market or private transaction on 2026-08-21

Shares owned after transaction 4,000 shares Indirect ownership via Traditional IRA after 2026-08-21 purchase

Key Terms

Form 4, Traditional IRA, Rule 10b5-1, indirect ownership

4 terms

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Traditional IRA financial

"nature_of_ownership": "Traditional IRA""

Rule 10b5-1 regulatory

"aff_10b5_one is the filing's document-level Rule 10b5-1 checkbox"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

indirect ownership financial

"ownership_type": "indirect""

FAQ

What insider transaction did BNGO report for Albert Luderer?

Albert Luderer indirectly purchased 4,000 shares of Bionano Genomics, Inc. Common Stock on 2026-08-21 at $1.215 per share, with the shares held through a Traditional IRA.

Was the recent BNGO insider trade a purchase or sale?

The reported insider trade was a purchase. Albert Luderer acquired 4,000 shares of Bionano Genomics, Inc. Common Stock at $1.215 per share on 2026-08-21.

How many BNGO shares does Albert Luderer hold after this transaction?

After the 2026-08-21 transaction, the reported indirect holdings for Albert Luderer related to this account are 4,000 shares of Bionano Genomics, Inc. Common Stock.

How is Albert Luderer’s BNGO stock ownership classified in this Form 4?

The 4,000 Bionano Genomics, Inc. shares are reported as indirectly owned, with the nature of ownership specified as a Traditional IRA.

Was the BNGO insider purchase made under a Rule 10b5-1 plan?

The filing indicates the Rule 10b5-1 checkbox is not checked, so this reported purchase of 4,000 Bionano Genomics, Inc. shares is not affirmed as being under a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/21/2026 - 04:31 PM Accepted by SEC EDGAR 08/21/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Luderer Albert

(Last) (First) (Middle)

C/O BIONANO GENOMICS, INC.

9540 TOWNE CENTRE DRIVE, SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bionano Genomics, Inc. [ BNGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim Chief Executive

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/21/2026		P		4,000	A	$1.215	4,000	I	Traditional IRA

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Jonathan V. Dixon, Attorney-in-Fact	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)